参考文献/References:
[1] Ahlin E,Mathsson L,Eloranta ML,et al.Autoantibodies associated with RNA are
more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE
[J].Lupus,2012,21(6):586-595.
[2] Sthoeger Z,Sharabi A,Mozes E.Novel approaches to the development of targeted
therapeutic agents for systemic lupus erythematosus[J].J Autoimmun, 2014, 54(11):
60-71.
[3] Lourenco EV, Procaccini C, Ferrera F, et al.Modulation of p38 MAPK activity in
regulatory T cells after tolerance with anti-DNA Ig peptide in(NZB x NZW)F1 lupus
mice[J].J Immunol,2009,182(12):7415-7421.
[4] Dinesh R,Hahn BH,La Cava A,et al.Interferon-in-decible gene 202b controls
CD+ T cell-mediated suppression in anti-DNA Ig petide-treated(NZB/NZW)F1
lupus mice[J].Genes Immun,2011,12(5):360-369.
[5] Skaggs BJ,Lourenco EV,Hahn BH.Oral administration of different forms of a
tolerogenic peptide to define the preparations and doses that delay anti-DNA
antibody production and nephritis and prolong survival in SLE-prone mice
[J].Lupus,2011,20(9):912-920.
[6] Hahn BH,Anderson M,Le E,et al.Anti-DNA Ig peptides promote Treg cell activity
in systemic lupus erythematosus patients[J].Arthritis Rheum,2008,58(8):2488-2497.
[7] Eggert M,Zettl UK,Neeck G.Autoantibodies in autoimmune diseases[J].Curr Pharm
Des,2010,16(14):1634-1643.
[8] Doyle HA,Aswad DW,Mamula MJ.Autoimmunity to isomerized histone H2B in systemic
lupus erythematosus[J].Autoimmunity,2013,46(1):6-13.
[9] Kang HK, Liu M, Datta SK.Low-dose peptide tolerance therapy of lupus generates
plasmacytoid dendritic cells that cause expansion of autoantigen-specific
regulatory T cells and contraction of inflammatory Th17 cells[J].J Immunol,
2007,178(12):7849-7858.
[10] Kang HK,Chiang MY,Liu M,et al.The histone peptide H471–94 alone is
more effective than a cocktail of peptide epitopes in controlling lupus:
immunoregulatory mechanisms[J].J Clin Immunol,2011,31(3):379-394.
[11] Zhang L, Bertucci AM, Ramsey-Goldman R, et al.Major pathogenic steps in human
lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced
regulatory immunity[J].Clin Immunol,2013,149(3):365-378.
[12] Briand JP, Schall N, Muller S.Generation of self-peptides to treatment
systemic lupus Erythematosus[J].Methods Mol Bio,2014,1134(1064-3745):173-192.
[13] Muller S,Monneaux F,Schall N,et al.Spliceosomal peptide P140 for immunotherapy
of systemic lupus erythematosus: results of an early phase II clinical trial
[J].Arthritis Rheum,2008,58(12):3873-3883.
[14] Zimmer R,Scherbarth HR,Rillo OL,et al.Lupuzor/P140 peptide in patients with
systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase
IIb clinical trial[J].Ann Rheum Dis,2013,72(11):1830-1835.
[15] Sthoeger ZM,Dayan M,Tcherniack A,et al.Modulation of autoreactive responses of
peripheral blood lymphocytesof patients with systemic lupus erythematosus by
peptides based on human and murine anti-DNA autoantibodies[J].Clin Exp
Immunol,2003,131(2):385-392.
[16] Sharabi A,Luger D,Ben-David H,et al.The role of apoptosis in the ameliorating
effects of a CDR1-based peptide on lupus manifestations in a mouse model[J].J
Immunol,2007,179(8):4979-4987.
[17] Parameswaran R,Ben David H,Sharabi A,et al.B-cell activating factor(BAFF)plays
a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus
[J].Clin Immunol,2009,131(2):223-232.
[18] Telerman A,Lapter S,Sharabi A,et al.Induction of hippocampal neurogenesis by
atolerogenic peptide that ameliorates lupus manifestations[J].J
Neuroimmunol,2011,232(1-2):151-157.
[19] Sthoeger Z,Sharabi A,Dayan M,et al.The tolerogenic peptide hCDR1 down
regulates pathogenic cytokines and apoptosis and upregulates immunosuppressive
molecules and regulatory T cells in peripheral blood mononuclear cells of lupus
patients[J].Hum Immunol,2009,70(3):139-145.
[20] Sthoeger Z,Zinger H,Sharabi A,et al.The tolerogenic peptide, hCDR1, down-
regulates the expression of interferon-α in murine and human systemic lupus
erythematosus[J].PloS one,2013,8(3):e60394.
[21] Urowitz MB,Isenberg DA,Wallace DJ.Safety and efficacy of hCDR1(Edratide)in
patients with active systemic lupus erythematosus: results of phase II study
[J].Lupus Sci Med,2015,112(1):e000104.
[22] Ching KH,Burbelo PD,Tipton C,et al.Two major autoantibody clusters in systemic
lupus erythematosus[J].PLoS One,2012,7(2):e32001.
[23] Riemekasten G,Langnickel D,Enghard P,et al.Intravenous injection of a D1
protein of the Smith proteins postpones murine lupus and induces type 1 regulatory
T cells[J].J Immunol,2004,173(9):5835-5842.
相似文献/References:
[1]周莹.系统性红斑狼疮并发股骨头坏死研究进展[J].中国皮肤性病学杂志,2017,(08):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
ZHOU Ying.Osteonecrosis of the Femoral Head in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2017,(12):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
[2]李萌萌,陈涛,郭在培.肿瘤坏死因子相关弱凋亡诱导因子与相关皮肤病[J].中国皮肤性病学杂志,2013,(07):85.
LI Meng-meng,CHEN Tao,GUO Zai-pei.TWEAK and Related Dermatoses[J].The Chinese Journal of Dermatovenereology,2013,(12):85.
[3]伊力努尔·哈力甫,梁俊琴,胡凤侠,等.免疫球蛋白受体ⅡB和ⅢA基因多态性与新疆维吾尔族SLE的遗传易感性分析[J].中国皮肤性病学杂志,2018,(12):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
Yilinuer Halifu,LIANG Junqin,HU Fengxia,et al.Association of Polymorphisms in Immunoglobulin Receptor ⅡB and ⅢA Genes with Hereditary Susceptibility of Systemic Lupus Erythematosus in Xinjiang[J].The Chinese Journal of Dermatovenereology,2018,(12):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
[4]范思奇,曾平,秦刚,等.系统性红斑狼疮并发股骨头坏死危险因素的Meta分析[J].中国皮肤性病学杂志,2018,(12):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
FAN Siqi,ZENG Ping,QIN Gang,et al.Meta-analysis of Risk Factors for Aseptic Femoral Head Necrosis in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2018,(12):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
[5]熊梦燎,李卉,周文明.皮肌炎和系统性红斑狼疮重叠综合征伴Degos样皮疹1例[J].中国皮肤性病学杂志,2020,(08):915.[doi:10.13735/j.cjdv.1001-7089.201909066]
XIONG Mengliao,LI Hui,ZHOU Wenming.A Case of Degos-like Lesions in Systemic Lupus Erythematosus-Dermatomyositis Overlap Syndrome[J].The Chinese Journal of Dermatovenereology,2020,(12):915.[doi:10.13735/j.cjdv.1001-7089.201909066]